MMSE
CAS: 177714-21-5
Ref. 3D-FM30736
1mg | Discontinued | ||
2mg | Discontinued | ||
5mg | Discontinued | ||
10mg | Discontinued | ||
25mg | Discontinued |
Product Information
- 3-Methoxymethyl-16a,17b-epiestriol-O-cyclic sulfone
- 3-O-Methoxymethyl-16,17-O-Sulfuryl-16-Epiestriol
- Estra-1,3,5(10)-Triene-16,17-Diol, 3-(Methoxymethoxy)-, Cyclic Sulfate, (16Alpha, 17Beta)
- Mmse
- 3-(Methoxymethoxy)-1,3,5(10)-gonatriene-16beta,17beta diol-16,17-cyclic sulfate
- Estra-1,3,5(10)-triene-16,17-diol,
- 3-Methoxymethyl-16 beta,17beta-epiestriol-O-cyclic sulfone
- Estra-1,3,5(10)-triene-16,17-diol, 3-(methoxymethoxy)-, cyclic sulfate, (16beta,17beta)
The Montreal Cognitive Assessment is a clinical cognitive test that evaluates mental status and cognitive function. It is an objective, repeatable, and standardized measure of cognitive function. The MMSE is used in the diagnosis of cerebrovascular disease, Alzheimer's disease, and other types of dementia. The MMSE was developed in 1996 by psychologists Luc Beaudoin (deceased) and Paul Bélanger to assess cognitive impairment in elderly patients. It is not intended for use as a diagnostic tool but rather as a screening instrument for detecting subtle memory problems or other early signs of dementia. The MMSE takes 10 minutes to administer and consists of 11 questions grouped into four categories: orientation, attention, memory, and language skills. An individual's score can be compared with norms established by age groupings.
The MMSE has been translated into more than 30 languages.br>br>
The MMSE can be administered to individuals aged 16 years or older who are suspected to have some form of